# Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

> **NCT04436029** · PHASE2 · COMPLETED · sponsor: **Cartesian Therapeutics** · enrollment: 5 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Descartes 11

## Key facts

- **NCT ID:** NCT04436029
- **Lead sponsor:** Cartesian Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-24
- **Primary completion:** 2022-02-18
- **Final completion:** 2022-04-09
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04436029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04436029, "Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04436029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*